Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Kroll MD

Michael H. Kroll MD

Professor of Medicine and Chief, Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Dr. Michael Kroll is a hematologist and oncologist practicing in Houston, Texas. He is Professor of Medicine and Chief of the Section of Benign Hematology at the University of Texas MD Anderson Cancer Center (UTMDACC). His basic research background is in mechanisms of platelet-dependent thrombosis, and his academic clinical niche is benign hematology, hemostasis and thrombosis. His group’s research activities focus on mechanisms of cancer- and stem cell transplant–associated thrombotic microangiopathy, the prevention and treatment of venous thromboembolism in cancer patients, and mechanisms of cancer-induced venous thrombosis.

Dr. Kroll is intimately involved in fellowship training, co-directs UTMDACC’s Anticoagulant Stewardship Program, has published over 100 manuscripts in peer-reviewed journals, lectures world-wide over a dozen times per year, serves on 2 federal grant review committees, has received several awards for education and leadership, and has served The American Society of Hematology in various capacities.

Dr. Kroll received his medical degree from Cornell. He underwent residency training in internal medicine at Brown University and completed his fellowship in hematology/oncology at Harvard Medical School–Brigham & Women's Hospital.

Disclosures

Incyte DSMB

Recent Contributions to PracticeUpdate:

  1. Apixaban for the Treatment of VTE Associated With Cancer
  2. Outcomes Associated With Oral Anticoagulants Plus Antiplatelets for Newly Diagnosed Atrial Fibrillation
  3. Prevalence of Confirmed Antiphospholipid Syndrome in Unselected Patients With First Unprovoked VTE
  4. Splanchnic Vein Thromboses Associated With Myeloproliferative Neoplasms
  5. The Role of Anti-Complement Factor H Antibodies in the Development of Atypical Hemolytic Uremic Syndrome
  6. ASH 2019 Guidelines for Immune Thrombocytopenia
  7. ASH 2019 Guidelines for Management of VTE: Prevention of VTE in Surgical Hospitalized Patients
  8. 2019 Top Stories in Benign Hematology: Chemotherapy-Induced Thrombocytopenia
  9. Costs Associated With Bleeding in Patients on Long-Term Antiplatelets Without Routine Co-Prescription of PPIs
  10. FDA Approves First Treatment to Increase Pain-Free Light Exposure in Patients With a Rare Disorder

Most Read This Week

Recently Updated